Education
About Us
Working with TipRanks
Follow Us
Coya Therapeutics, Inc. (COYA)
NASDAQ:COYA
COYA Stock Chart & Stats
$6.02
-$0.10(-1.62%)
At close: 4:00 PM EST
$6.02
-$0.10(-1.62%)
Day’s Range― - ―
52-Week Range$4.65 - $8.29
Previous CloseN/A
Volume16.99K
Average Volume (3M)209.41K
Market Cap
$125.97M
Enterprise Value$67.25M
Total Cash (Recent Filing)$28.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Mar 24, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding20,924,456
10 Day Avg. Volume121,785
30 Day Avg. Volume209,410
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)2.21
Price to Sales (P/S)24.57
P/FCF Ratio-8.49
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue16.86
Enterprise Value/Gross Profit-21.16
Enterprise Value/Ebitda-3.37
Forecast
1Y Price Target
$17.50Price Target Upside190.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.25
Revenue Forecast (FY)$5.91M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe ALS trial agreement on testing two immune-modulators shows regulatory progress and potential effectiveness in treating inflammatory diseases.
Financial ResourcesCoya Therapeutics recently completed an equity financing, resulting in total gross proceeds of $23M, providing sufficient resources to fund operations into 2H27.
Regulatory ProgressFDA's acceptance of the IND for COYA 302 allows it to enter the next stage of clinical development, triggering a $4.2M milestone payment.
Bears Say
Clinical SetbacksClinical setbacks involving COYA 302 in ALS and/or AD could pose significant risks.
Market UptakePoorer-than-anticipated commercial uptake of COYA 302 presents possible risks.
Regulatory ApprovalRisks include the failure to secure U.S. regulatory approval for COYA 302 in ALS and/or AD.
Coya Therapeutics, Inc. News
COYA FAQ
What was Coya Therapeutics, Inc.’s price range in the past 12 months?
Coya Therapeutics, Inc. lowest stock price was $4.65 and its highest was $8.29 in the past 12 months.
What is Coya Therapeutics, Inc.’s market cap?
Coya Therapeutics, Inc.’s market cap is $125.97M.
When is Coya Therapeutics, Inc.’s upcoming earnings report date?
Coya Therapeutics, Inc.’s upcoming earnings report date is Mar 24, 2026 which is in 108 days.
How were Coya Therapeutics, Inc.’s earnings last quarter?
Coya Therapeutics, Inc. released its earnings results on Sep 30, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.233 by $0.103.
Is Coya Therapeutics, Inc. overvalued?
According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued.
Does Coya Therapeutics, Inc. pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
What is Coya Therapeutics, Inc.’s EPS estimate?
Coya Therapeutics, Inc.’s EPS estimate is -0.28.
How many shares outstanding does Coya Therapeutics, Inc. have?
Coya Therapeutics, Inc. has 20,924,456 shares outstanding.
What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?
Coya Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.233. Following the earnings report the stock price went up 0.707%.
Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?
Currently, no hedge funds are holding shares in COYA
Coya Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.50 (190.70% Upside)
$17.50 (190.70% Upside)
Blogger Sentiment
Bullish
COYA Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.66%
12-Months-Change
Fundamentals
Return on Equity
-62.18%
Trailing 12-Months
Asset Growth
-9.87%
Trailing 12-Months
Company Description
Coya Therapeutics, Inc.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
COYA Stock 12 Month Forecast
Average Price Target
$17.50
▲(190.70% Upside)
Technical Analysis
Ownership Overview
4.95% Insiders
4.69% Mutual Funds
15.82% Other Institutional Investors
70.93% Public Companies and
Individual Investors